# A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Source: https://onco.cc/trials/nct06198751/  
OnCo record `nct06198751` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of TQB2102 in HER2-positive breast cancer, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., active and no longer recruiting.

## Summary

A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer is a phase 2 interventional study registered as NCT06198751 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 104 participants enrolled, started 2024-02-05 and due to reach its primary completion in 2025-05-08. Interventions recorded: 6.0 mg/kg of TQB2102 for injection and 7.5 mg/kg of TQB2102 for injection.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06198751
- Phase: 2
- Setting: A Phase 2, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of TQB2102 for Injection for Neoadjuvant Treatment of Breast Cancer With Positive HER2 Expression
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Enrolled: 104

## Sources

- ClinicalTrials.gov NCT06198751: https://clinicaltrials.gov/study/NCT06198751

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [TQB2102](https://onco.cc/drugs/tqb2102/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct06198751.json